Depressive DisordersPalliative & End-of-Life DistressAnxiety DisordersMDMA

Oxytocin-dependent reopening of a social reward learning critical period with MDMA

This mice study investigates the restoration/regulation of social reward learning for patients with long-term depression using MDMA. The findings point towards the potential of understanding the pathogenesis of neurodevelopmental diseases, which are defined by social impairments, and of disorders that are effected by social influence or are a consequence of social injury.

Authors

  • Nardou, R.
  • Lewis, E. M.
  • Rothhaas, R.

Published

Nature
individual Study

Abstract

A critical period is a developmental epoch during which the nervous system is expressly sensitive to specific environmental stimuli that are required for proper circuit organization and learning. Mechanistic characterization of critical periods has revealed an important role for exuberant brain plasticity during early development, and for constraints that are imposed on these mechanisms as the brain matures. In disease states, closure of critical periods limits the ability of the brain to adapt even when optimal conditions are restored. Thus, identification of manipulations that reopen critical periods has been a priority for translational neuroscience. Here we provide evidence that developmental regulation of oxytocin-mediated synaptic plasticity (long-term depression) in the nucleus accumbens establishes a critical period for social reward learning. Furthermore, we show that a single dose of (+/−)-3,4-methylendioxymethamphetamine (MDMA) reopens the critical period for social reward learning and leads to a metaplastic upregulation of oxytocin-dependent long-term depression. MDMA-induced reopening of this critical period requires activation of oxytocin receptors in the nucleus accumbens, and is recapitulated by stimulation of oxytocin terminals in the nucleus accumbens. These findings have important implications for understanding the pathogenesis of neurodevelopmental diseases that are characterized by social impairments and of disorders that respond to social influence or are the result of social injury.

Available with Blossom Pro

Research Summary of 'Oxytocin-dependent reopening of a social reward learning critical period with MDMA'

Introduction

A critical period denotes a developmental window when the nervous system is highly sensitive to particular environmental stimuli required for appropriate circuit formation and learning. Earlier work has shown that exuberant plasticity during early development and subsequent maturation-imposed constraints shape these windows, and that once closed they can limit adaptive responses in disease. In this context, oxytocin (OT) signalling in the nucleus accumbens (NAc) has been implicated in juvenile social reward learning via a presynaptically expressed long-term depression (LTD) of excitatory synapses. Nardou and colleagues set out to test whether developmental regulation of OT-dependent synaptic plasticity establishes a critical period for social reward learning, and whether that period can be reopened. They examined the maturational trajectory of social conditioned place preference (social CPP) across mouse ages, tested age-dependent expression of OT-LTD in the NAc, and asked whether MDMA (±3,4-methylenedioxymethamphetamine) or direct stimulation of OT terminals can reinstate juvenile-like plasticity and behaviour in adults. The study aims to link cellular mechanisms in the NAc with behavioural critical-period regulation and to probe mechanistic requirements for any reopened window.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Full Text PDF

Full Paper PDF

Create a free account to open full-text PDFs.

Study Details

References (3)

Papers cited by this study that are also in Blossom

Potential Psychiatric Uses for MDMA

Yazar-Klosinski, B., Mithoefer, M. C. · Clinical Pharmacology and Therapeutics (2016)

Cited By (30)

Papers in Blossom that reference this study

Psychedelic therapy and postpartum depression: priorities and prospects

Thuery, G., Crossen, F., Mc Loone, D. et al. · Therapeutic Advances in Psychopharmacology (2026)

Psychedelic medicine: mechanisms, evidence, and translation to practice

Jacobs, E., Zahid, Z., Hinkle, J. et al. · BMJ (2026)

A multi-institutional investigation of psilocybin's effects on mouse behavior

Lu, O. D., White, K., Raymond, K. et al. · Biorxiv (2025)

The 3,4-methylenedioxymethamphetamine enhances early visual processing for salient socio-emotional stimuli

Haggarty, C. J., Bershad, A. K., Kumar, M. K. et al. · European Journal of Neurology (2024)

2 cited
Learned Helplessness As a Potential Transdiagnostic Therapeutic Mechanism of Classic Psychedelics

Tiwari, P., Sayali, C., Doss, M. K. et al. · Psychedelic Medicine (2023)

Psychedelics reopen the social reward learning critical period

Nardou, R., Sawyer, E., Song, Y. J. et al. · Nature (2023)

Canalization and plasticity in psychopathology

Carhart-Harris, R. L., Chandaria, S., Erritzoe, D. E. et al. · Neuropharmacology (2023)

Can psychedelics enhance group psychotherapy? A discussion on the therapeutic factors

Ponomarenko, P., Seragnoli, F., Calder, A. et al. · Journal of Psychopharmacology (2023)

Show all 30 papers
Altered brain activity and functional connectivity after MDMA-assisted therapy for post-traumatic stress disorder

Singleton, S. P., Wang, J. B., Mithoefer, A. T. et al. · Frontiers in Psychiatry (2023)

48 cited
MDMA-assisted therapy is associated with a reduction in chronic pain among people with post-traumatic stress disorder

Christie, D., Yazar-Klosinski, B., Nosova, E. et al. · Frontiers in Psychiatry (2022)

7 cited
MDMA-Assisted Psychotherapy for Borderline Personality Disorder

Traynor, J. M., Roberts, D. E., Ross, S. et al. · Focus (2022)

Pharmacological, Neural, and Psychological Mechanisms underlying Psychedelics: A Critical Review

van Elk, M., Yaden, D. B. · Neuroscience and Biobehavioral Reviews (2022)

Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review

Sarparast, A., Thomas, K., Malcolm, B. et al. · Psychopharmacology (2022)

Psychedelic-Assisted Therapy for Substance Use Disorders and Potential Mechanisms of Action

Rieser, N. M., Herdener, M. ;., Preller, K. H. · Current Topics in Behavioral Neurosciences (2021)

Critical Period Plasticity as a Framework for Psychedelic-Assisted Psychotherapy

Yehuda, R., Lepow, L., Morishita, H. · Frontiers in Neuroscience (2021)

A Systematic Review of the MDMA Model to Address Social Impairment in Autism

Chaliha, D., Mamo, J. C., Albrecht, M. et al. · Current Neuropharmacology (2021)

3 cited
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study

Mitchell, J., Bogenschutz, M. P., Lilienstein, A. et al. · Nature Medicine (2021)

The History of Psychedelics in Psychiatry

Nichols, D. E., Walter, H. · Pharmacopsychiatry (2020)

Reviewing the potential of psychedelics for the treatment of PTSD

Krediet, E., Bostoen, T., Breeksema, J. J. et al. · International Journal of Neuropsychopharmacology (2020)

Emotions and brain function are altered up to one month after a single high dose of psilocybin

Barrett, F. S., Doss, M. K., Sepeda, N. D. et al. · Scientific Reports (2020)

Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for posttraumatic stress disorder: A systematic review and meta-analysis.

Bahji, A., Forsyth, A., Groll, D. et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2020)

61 cited
Modulation of Social Cognition via Hallucinogens and “Entactogens”.

Preller, K. H., Vollenweider, F. X. · Frontiers in Psychiatry (2019)

Breakthrough for trauma treatment: safety and efficacy of MDMA-assisted psychotherapy compared to paroxetine and sertraline

Feduccia, A. A., Jerome, L., Yazar-Klosinski, B. et al. · Frontiers in Psychiatry (2019)

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.